ABVC BioPharma receives a $100,000 milestone licensing payment from ForSeeCon Eye Corporation, marking progress in developing ophthalmic drugs. The partnership aims to advance Vitargus® into pivotal trials in 2025, with potential value reaching $1.0 billion. ABVC focuses on innovative product pipeline growth and global partnerships in the thriving $110.3 billion eye care market.
